BioStock: CombiGene’s CEO on the FDA approval of Hemgenix

As gene therapies advance through clinical trials, more and more of these treatments are receiving approval from the U.S. Food and Drug Administration and its European counterpart, the European Medicines Agency. The latest in line to gain approval by the FDA was CSL Behring’s hemophilia B gene therapy Hemgenix. With a price tag of 3.5 MUSD per dose, Hemgenix will be the most expensive medicine in the world. BioStock reached out to Jan Nilsson, CEO of the Swedish gene therapy company CombiGene, for a comment.

Read the full interview with CombiGene's CEO Jan Nilsson at biostock.se:

https://www.biostock.se/en/2022/12/combigenes-ceo-on-the-fda-approval-of-hemgenix/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/